Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

ZAI Lab In-licenses Potential Liver Cancer Drug from BMS

publication date: Mar 22, 2015
ZAI Lab of Shanghai has in-licensed China rights to a liver cancer drug candidate from Bristol-Myers Squibb. Brivanib is an oral kinase inhibitor that is in Phase III trials for oncology indications including hepatocellular carcinoma, which is especially prevalent in China. ZAI Lab will be responsible for developing, manufacturing and commercializing brivanib in China, though BMS will have an option to co-promote the drug. ZAI will pay BMS development milestones and tiered royalties if brivanib is approved in China. More details....

Stock Symbol: (NYSE: BMY)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital